Personalized Treatment for Coronary Artery Disease Patients: A Machine
  Learning Approach by Bertsimas, Dimitris et al.
Personalized Treatment for Coronary Artery Disease
Patients: A Machine Learning Approach
Dimitris Bertsimas
Sloan School of Management, Massachusetts Institute of Technology, Cambridge, dbertsim@mit.edu
Agni Orfanoudaki
Operations Research Center, Massachusetts Institute of Technology, Cambridge, agniorf@mit.edu
Rory B. Weiner
Cardiology Division, Massachusetts General Hospital, Boston, rweiner@partners.org
Current clinical practice guidelines for managing Coronary Artery Disease (CAD) account for general cardio-
vascular risk factors. However, they do not present a framework that considers personalized patient-specific
characteristics. Using the electronic health records of 21,460 patients, we created data-driven models for
personalized CAD management that significantly improve health outcomes relative to the standard of care.
We develop binary classifiers to detect whether a patient will experience an adverse event due to CAD within
a 10-year time frame. Combining the patients’ medical history and clinical examination results, we achieve
81.5% AUC. For each treatment, we also create a series of regression models that are based on different
supervised machine learning algorithms. We are able to estimate with average R2 = 0.801 the time from diag-
nosis to a potential adverse event (TAE) and gain accurate approximations of the counterfactual treatment
effects. Leveraging combinations of these models, we present ML4CAD, a novel personalized prescriptive algo-
rithm. Considering the recommendations of multiple predictive models at once, ML4CAD identifies for every
patient the therapy with the best expected outcome using a voting mechanism. We evaluate its performance
by measuring the prescription effectiveness and robustness under alternative ground truths. We show that
our methodology improves the expected TAE upon the current baseline by 24.11%, increasing it from 4.56
to 5.66 years. The algorithm performs particularly well for the male (24.3% improvement) and Hispanic
(58.41% improvement) subpopulations. Finally, we create an interactive interface, providing physicians with
an intuitive, accurate, readily implementable, and effective tool.
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1. Introduction
The clinical condition of Coronary Artery Disease (CAD), also referred to as ischemic heart disease,
is present when a patient presents one or more symptoms or complications from an inadequate
blood supply to the myocardium (Fuster et al. 1992). This is most commonly attributed to the
obstruction of the epicardial coronary arteries due to atherosclerosis (Ross 1999). CAD remains
the number one cause of death in the United States, accounting for over 360,000 annual casualties
(AHA 2017). CAD is mostly prevalent in older patients (above the age of 50 years) in the form
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of a chronic condition which requires a principal intervention and subsequent systematic medical
therapy and monitoring (Fuster et al. 1992). The primary care of patients with CAD includes
ascertainment of the diagnosis and its severity (with non-invasive and/or invasive imaging), control
of symptoms, and therapies to improve survival (Hansson 2005). The mainstay of treatment is
medical therapy. The latter may or may not be combined with coronary revascularization (either
Coronary Artery Bypass Graft (CABG) surgery or Percutaneous Coronary Intervention (PCI)) in
an effort to slow the progress of the disease and relieve its symptoms. Considering the magnitude
and the repercussions of CAD, the importance of medical therapy to reduce its symptoms and
prolong life expectancy is being increasingly recognized (Sedlis et al. 2015).
There has been growing interest in using clinical evidence to understand the effects of treatments
in patients with CAD. Nowadays, there are numerous evidence-based clinical guidelines for CAD
management (Fihn et al. 2015, 2014) and angiographic tools for grading its complexity, such as
the SYNTAX Score (Serruys et al. 2009, Sianos et al. 2005). However, it is not clear how to
choose among different types of available therapies (pharmacological, percutaneous intervention,
and surgery) to maximize effectiveness at an individual level. This is likely due to the multitude of
parameters that define the form of the disease for each patient and the uncertainty that lies behind
an individual patient’s response to a particular treatment (Warnes 2017). One of the greatest
challenges in developing evidence-based guidelines applicable to large populations is paucity of
information about special subpopulations with unique characteristics. This is attributed to the
absence of specialized clinical trials (Fihn et al. 2014).
Considering the challenges and the significance of CAD, a personalization approach may greatly
impact the effective management of the disease. Personalization is the problem of identifying the
best treatment option for a given instance, i.e., a display add (Zhou et al. 2008) or medical therapy
(Lesko 2007). There are two main challenges for designing personalized prescriptions for a patient
as a function of the features recorded in the data:
1. While the outcome of the administered treatment for each patient is observed, the counter-
factual outcomes are unknown. That is, the outcomes that would have occurred had another
treatment been administered. Note that if this information were known, the prescription prob-
lem would reduce to a multi-class classification problem. Thus, the counterfactual outcomes
need to be inferred.
2. In the data, there is an inherent bias that needs to be taken into account. The nature of data
from Electronic Medical Records (EMR) is observational as opposed to data from randomized
trials. In a randomized trial setting, patients are randomly assigned different treatments, while
in an observational setting, the assignment of treatments potentially depends on features of
the population.
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1.1. Literature Review
Our objective is to solve the problem of prescribing the best option among a set of predefined treat-
ments to a given patient as a function of the samples’ features. We are provided with observational
data of the form {(xi, yi, zi)}ni=1, comprising n observations. Each data point {(xi, yi, zi)} is char-
acterized by features xi ∈Rp, the prescribed treatment zi ∈ [T ] = {1, . . . ,T}, and the corresponding
outcome yi ∈R. We denote y(1), . . . , y(T ) the T “possible outcomes” resulting from assigning each
of the T treatments respectively.
A similar question has been studied in the causal inference literature. In this setting, the main
focus lies on observational studies to identify causal relationships between an intervention and
outcomes in a particular population (Pearl et al. 2009). Introduced by Neyman and popularized by
Rubin, the Potential Outcomes Framework uses a probabilistic assignment mechanism to mathe-
matically describe how treatments are given to patients. It also accounts for a potential dependence
on background variables and the potential outcomes themselves (Rubin 1990, Angrist et al. 1996).
More specifically, it focuses on the case where S = {C,T} (treatment and control). For each patient
i, the potential outcome yi(T ) is the experienced outcome if exposed to treatment T . The causal
effect of T compared to C is then computed as δi ∶= yi(T )− yi(C). Thus, causal effects are solely
defined for one treatment relative to another and only if the individual could have been reasonably
exposed to both. The fundamental problem of causal inference is that (yi(T ), yi(C)) are not jointly
observable. That is, only one observed response is present depending on the treatment assignment.
As a result, Rosenbaum and Rubin (1983) focus on the average treatment effect for a completely
randomized experiment. This scenario considers the difference of the sample means for the units
receiving the treatment and control.
ATE = 1
nT
∑
j∶zj=T yj(T )− 1nC ∑j∶zj=C yj(C). (1)
However, in observational studies, treatment assignment is not independent of the potential out-
comes. Thus, further analysis is required to account for latent differences between the treated and
control groups on the basis of observed covariates X (inverse probability weighting, propensity
score matching, nonparemetric regression, etc.) (Rosenbaum 2010).
Causal effect approaches do not provide personalized estimations of the treatment effect for each
unit since they focus on the aggregate population level. A personalized prescription methodology
would require a quantification of the impact of each regimen for every individual in isolation.
This is the essence of the personalized medicine field (Hamburg and Collins 2010): identifying the
optimal therapy for a particular set of phenotypic and genetic patient characteristics. Machine
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learning (ML) algorithms are expected to enable the utilization of rich datasets. They could provide
improved solutions for patients by learning the outcome function for each treatment. They will
particularly impact those that belong to very specific subgroups and respond in unusual ways to
the available treatments (Fro¨hlich et al. 2018).
A common approach in the literature to leverage these algorithms is called “Regress and Com-
pare”. It identifies the expected effect yi(zi) of treatment zi ∈ [T ] for each patient i based on the
covariates xi and consequently prescribes the regimen with the best potential impact;
max
zi∈[T ]yi(zi∣xi) ∀i ∈ [n],
where [n] is the set of patients in the sample. The “Regress and Compare” methodology follows
this paradigm, choosing a treatment by maximizing among T regression functions. A different
regression model is fitted to the subset of the data that received each treatment. It subsequently
uses them to predict outcomes and pick the one with the more optimistic prediction (Stoehlmacher
et al. 2004). This approach has been historically followed by several authors in clinical research
(Feldstein et al. 1978), and more recently by researchers in statistics (Qian and Murphy 2011)
and operations research (Bertsimas et al. 2017). The online version of this problem, called the
contextual bandit problem, has been studied by several authors (Li et al. 2010, Goldenshluger and
Zeevi 2013) in the multi-armed bandit literature (Gittins et al. 1989). Even though it is intuitive,
this methodology is subject to prediction errors and potential biases of a single method.
In the field of precision medicine, Bertsimas et al. (2017), first, introduced a personalized pre-
scriptive algorithm for diabetes management that harnesses the power of EMR. It was based on
a “Regress and Compare” k nearest neighbors (k-NN) approach. This methodology yielded sub-
stantial improvements in patient outcomes relative to the standard of care. Moreover, it provided
physicians with a prototyped dashboard visualizing the algorithm’s recommendations. Their work
showed that tailored approaches to particular diseases coupled with medical expertise provide the
medical community with highly accurate and effective tools that will ameliorate patient treatment.
Even though this effort provided promising results, the k-NN approach is not applicable to diseases
where the effects of a treatment are not promptly observable. The same individual was tracked via
multiple visits in the hospital system. Thus, the algorithm suggested alterations in the medication
only when there was significant reduction on the expected Hemoglobin A1c measurement. The
physician could measure the effectiveness of a treatment by ordering a blood test in the near future.
On the contrary, at the CAD setting the adverse effects of the disease are observed in the span of
ten years from the time of diagnosis.
4
Focusing mostly on the personalization and not the prediction objective, Kallus (2017) proposes
a recursive partitioning methodology for personalization using observational data. This new algo-
rithm is tailored to optimize a personalization impurity measure. As a result, it hardly places any
emphasis on the predictive task. Therefore, it raises questions regarding the accuracy of the sug-
gested treatment effect. Bertsimas et al. (2019) modify the latter’s objective to account for the
prediction error, and use the methodology of Bertsimas and Dunn (2019, 2017) to design near
optimal trees, improving performance substantially. Continuing on tree based approaches, Athey
and Imbens (2016), and Wager and Athey (2018) also use a recursive splitting procedure of the
feature space to construct causal trees and causal forests respectively. They estimate the causal
effect of a treatment for a given sample, or construct confidence intervals for the treatment effects.
However, they do not infer explicit prescriptions or recommendations. Also, causal trees (or forests)
are designed exclusively for studies comparing binary treatments.
In the cardiovascular field, the benefit of ML based personalization methods has been recognized
and is expected to play a significant role in facilitating precision cardiovascular medicine (Krittana-
wong et al. 2017). Nevertheless, in the case of CAD, personalization approaches have been primarily
focused on utilizing genomic information (Beitelshees 2012), and not on employing EMR and ML.
Since 2014, the US mandated all public and private healthcare providers to adopt and demonstrate
“meaningful use” of EMR to maintain their existing Medicaid and Medicare reimbursement levels.
This decision contributed to the creation of clinical databases that contain in-depth information
for many patients. These data can be leveraged using ML to construct models and algorithms that
can learn from and make predictions on data (Ron Kohavi 1998).
One of the greatest challenges of EMR is the presence of right censored patients (Lagakos 1979,
Imbens and Rubin 2015), which arises when a patient disappears from the database after diagnosis
and treatment of the disease. Traditional approaches to address right censoring, including the Cox
proportional hazards model (Cox 1972) or the Weibull Regression (K. Ghosh 2003), do not allow
for time-varying effects of covariates. Their weaknesses are especially relevant to datasets that span
over long periods of time, providing results that are not validated by the medical literature (e.g.
positive correlation between a patient’s BMI and his/her expected time to adverse event).
Our work addresses most of the challenges encountered in the personalized prescription setting
that uses EMR, including counterfactual estimation and censoring.
1.2. Contributions
In this paper, our objective is to find the best primary treatment for a CAD patient to maxi-
mize the time from diagnosis to a potential adverse event (TAE) (myocardial infarction or stroke).
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Our dataset includes CAD patients who were administered treatment through the Boston Medical
Center (BMC), a private, not-for-profit, 487-bed, academic medical center located in Boston, MA,
USA. We retrieved each patient’s medical history, the primary treatment followed after diagnosis
and the most recent clinical examination results to the time of diagnosis. We considered five pri-
mary prescription approaches available for each patient. We developed predictive and prescriptive
algorithms that provide personalized treatment recommendations. We propose a new prescription
algorithm to assign the regimen with the best predicted outcome leveraging simultaneously mul-
tiple regression models. The effect of the prescriptive algorithm was evaluated by comparing the
expected TAE under our recommended therapy with the observed outcome prescribed by physi-
cians at the medical center. We tested the robustness and effectiveness of our methodology. We
considered different ground truths regarding the treatment effect of a given therapy to a patient.
The ground truths comprise the standard of care as well as combinations or individual predictions
from ML models. The main contributions of this paper are:
1. A new methodology to treat right censored patients that utilizes a k-NN approach to estimate
the true survival time from real-world data.
2. Interpretable and accurate binary classification and regression models that predict the risk
and timing of a potential adverse event for CAD patients. We selected a diverse set of well-
established supervised machine learning algorithms for these tasks.
3. The first prescriptive methodology that utilizes EMR to provide treatment recommendations
for CAD. Our algorithm, ML4CAD (Machine Learning for CAD), combines multiple state-of-
the-art ML regression models with clinical expertise at once. In particular, it uses a voting
scheme to suggest personalized treatments based on individual data.
4. A novel evaluation framework to measure the out-of-sample performance of prescriptive algo-
rithms. It compares counterfactual outcomes for multiple treatments under various ground
truths. Thus, we assess both the accuracy, effectiveness, and robustness of our prescriptive
methodology. Using this evaluation mechanism, we demonstrate that ML4CAD improves upon
the standard of care. Its expected benefit was validated by all considered ground truths and
TAE estimation models.
5. An online application where physicians can test the performance of the algorithm in real time
bridging the gap with the clinical practice.
The structure of the paper is as follows. In Section 2, we describe the data used to train and
validate our methods. In Section 3, we outline the method used to handle the challenge of censoring.
Section 4 describes the methods and results of the binary classification models, and similarly
Section 5 refers to regression. In Section 6, we present the personalized prescription algorithm and
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its evaluation framework. Results under different ground truths and recommendation policies are
compared in Section 7. We conclude our work in Section 8.
2. Data
In this section, we provide detailed information about the dataset under consideration. We outline
the patient inclusion criteria as well as a description of the covariates included in the ML models.
Subsequently, we refer to the treatments identified from the EMR and their aggregation as features
for our algorithms. We also present the missing data imputation procedure that was followed.
Sample Population Description
Through a partnership with the BMC we obtained EMR for 1.1 million patients from 1982 to 2016.
In this dataset, 21,460 patients met, at least, one of the following inclusion criteria:
• Population 1: Patients associated with CAD risk of at least 10% based on the Framingham
Heart Study formula (Wilson et al. 1998) who were prescribed antihypertensive medication.
We used the 10% threshold since it is considered one of the primary indications for physicians
to prescribe CAD treatment to their patients (Wilson 2017);
• Population 2: Patients who were administered at least one CABG surgery or, at least, one
PCI and were prescribed antihypertensive medication;
We used the conditions outlined above due to the absence of a systematic CAD diagnosis code in
the system (Strom 2001). All patient EMR were processed to identify the time t0 that corresponds
to the point of initial diagnosis prior to any coronary revascularization. We reverted to the record
that corresponds to this time to create the patient features X. Thus, we avoided the inclusion
of two populations whose conditions are fundamentally dissimilar. Our sample comprised recently
diagnosed CAD patients, similar to the ones physicians encounter in practice. We identified, using
the totality of the EMR after the time t0, the main therapy prescribed to each patient while being
in the system. Notice that every member of the sample population was medicated with antihy-
pertensive drugs. If in addition to the pharmacological therapy they were administered surgical or
percutaneous interventions, we set the latter as the main treatment administered by the hospital.
BMC patients come predominantly from underprivileged socioeconomic backgrounds. As a result,
in most cases they do not have the financial capability to support alternative health providers. They
need to appeal to the BMC for healthcare services for the majority of their medical needs. Thus,
most of their EMR are concentrated in the same database, allowing us to follow the trajectory of
each patient’s health from a single source. The ethnicity and age distributions of the population
are depicted in Figures 1a and 1b, respectively.
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(a) Ethnicity distribution. (b) Age distribution.
Figure 1 Demographic Characteristics of the population
We excluded all patients whose diagnosis date was identical to their last observation in the
healthcare system. Moreover, we removed from the data those whose cause of death was observed
but not related to heart disease (e.g., cancer non-survivors). We retrieved for each patient a set
of values that describe their demographics, medical therapy, and clinical characteristics at the
time of diagnosis t0 (Table 1). We used ICD-9, CPT, and hospital specific codes to identify the
corresponding records as well as lab test results for particular measurements (i.e., low-density
lipoprotein (LDL) or high-density lipoprotein (HDL) levels). Along with demographic information,
we included features that are considered risk factors for heart disease, according to the medical
literature. We excluded all covariates whose values were not known for at least 50% of the patients
in the dataset. Further information regarding the characteristics of the overall population, as well
as split by training, validation, and testing set are available in the Appendix. We identified an
adverse event (myocardial infarction or stroke) attributable to CAD and recorded the date of
occurrence. This way, we define the time between a diagnosis and an adverse event. In case the
patient disappeared from the EMR before the lapse of 10 years after diagnosis, we recorded that
the patient was right censored. We did not take into account the severity of the adverse event in
our evaluation.
Treatment Options
We considered five primary options for each patient, shown in Table 2. CAD is a chronic disease
whose management may differ across time. However, we noticed that a certain pattern was followed
for the vast majority of the patients throughout their presence in the academic medical center.
Coronary revascularization is a major operation and thus we distinguish CABG and PCI as separate
treatment categories. In agreement with the general guidelines of the American Heart Association
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Demographics Treatment Family History Medical Records Observed Behavior
Age ACE inhibitors Diabetes Body Mass Index (BMI) Smoking
Gender Adrenergic Receptors Hypertension LDL Cholesterol Time observed in EMR database
Ethnicity Angiotensin Agonists HDL Cholesterol
Language Antiarrhythmics Diastolic Blood Pressure
Marital Status Blockers (beta, alpha, etc.) Systolic Blood Pressure
Ethnicity CABG Diabetes
Cardiac Glycosides
Diuretics
Lipid Lowering medication
Muscle relaxants
Nitrates
Other antihypertensive
PCI
Phosphodiesterase inhibitors
Statins
Table 1 Patient characteristics considered.
for the management of Stable Ischemic Heart Disease (Fihn et al. 2014), most of the patients are
prescribed blocking medication to treat hypertension and statins as a lipid lowering treatment.
Therefore, we chose combinations of those two lines of therapy as primary prescription options.
Nevertheless, the pharmaceutical treatment for a CAD patient may include not only blockers, but
also a more complicated combination of drugs, depicted in Table 3 under “Treatment”. As the set
of all those combinations is too wide, we considered only the most common prescription options.
We did not account for aspirin (ASA) since all patients were prescribed this line of therapy.
Note that we did not consider ACE inhibitors as a prescription option because they usually
accompany another type of antihypertensive medication for CAD patients (Rejnmark et al. 2006).
They are prescribed in combination to blockers or as a substitute of the latter in cases where a
patient has some prohibitive medical condition to the former. Thus, the majority of the population
that belongs in the “Drugs 2 and 3” categories are effectively under ACE inhibitors. The latter
drug class was administered in less than 50% of the sample population. As a result, a separate
pharmacological treatment option would thin the training sets presented in the following sections
significantly.
Handling of missing values
We collected each patient’s medical records (lab test results and clinical measurements) associated
with the most recent clinical examination before or at the time of diagnosis. We imputed missing
values using the state-of-the-art ML algorithm proposed by Bertsimas et al. (2018). We omitted
from our analysis any risk factors whose missing values proportion was higher than 50% (i.e.,
ejection fraction, ECG measurements).
9
Option Name Analysis
Number of
patients
% of the
population
CABG
Coronary Artery Bypass Graft Surgery
with pharmaceutical treatment
1854 8.64%
PCI
Percutaneous Coronary Intervention
with pharmaceutical treatment
4042 18.85%
Drugs 1
Pharmaceutical treatment
including blockers and statins
6833 31.86%
Drugs 2
Pharmaceutical treatment
including blockers and excluding statins
3767 17.56%
Drugs 3
Pharmaceutical treatment
excluding blockers (potentially including statins)
4964 23.09%
Table 2 The Prescription Options.
Treatment Name
Population
Proportion
Treatment Name
Population
Proportion
ACE inhibitors 46.12% Lipid Lowering medication 5.29%
Adrenergic Receptors 6.38% Muscle relaxants 4.81%
Angiotensin Agonists 13.62% Nitrates 77.02%
Antiarrhythmics 13.65% Other antihypertensive 11.37%
Blockers (beta, alpha, etc.) 68.03% PCI 19.60%
CABG 7.01% Phosphodiesterase inhibitors 3.59%
Cardiac Glycosides 2.45% Statins 58.78%
Diuretics 47.90%
Table 3 The percentage of the overall population that received each treatment based on the sample
population. Note that the same patient may have been prescribed multiple treatments.
3. Estimating time to adverse event for right censored patients
Our sample was comprised of 13,679 censored observations (62.9% of the overall population). In
censored datasets the outcome of interest is generally the time until an event (onset of disease,
death, etc.), but the exact time of the event is unknown (censored) for some individuals. When a
lower bound for these missing values is known (for example, a patient is known to be alive until
at least time t) the data is said to be right censored. In our dataset, we considered the time of
censoring to be the last event-free visit of the patient to the academic medical center. Thus, for
each patient i where ti < 10 (years) and no adverse event (stroke/heart attack) has been recorded,
we set the censoring time ci = ti, the last time observed in the EMR.
Methods from the survival analysis literature are usually employed in the presence of censored
populations. A common survival analysis technique is the Cox proportional hazards regression
(Cox 1972) which models the hazard rate for an event as a linear combination of covariate effects.
Although this model is widely used and easily interpreted, its parametric nature makes it unable
to identify non-linear effects or interactions between covariates (Bou-Hamad et al. 2011).
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We propose a data-driven methodology that utilizes a k-NN approach to identify patients with
similar outcomes and known trajectories based on their covariates. We consider the set A (B) of
patients that had (did not have) an adverse event within 10 years. Note that within set B the EMR
indicate that no adverse event occurred within the defined time frame. Let C be the set of censored
patients that did not have an adverse event within a time tc (less than 10 years) and they disappear
from the EMR after tc. It is not known whether they experienced an adverse event within 10 years
or not. In order to estimate the TAE for patient X in the set C, we consider patients within A∪B
such that:
1. They have the same gender as X. It has been recognized that women form a distinct subpop-
ulation within patients with CAD (Roeters van Lennep et al. 2002).
2. They belong to the same age group as X. Age at time of diagnosis plays a major role in the
development and the effects of CAD (Wilson et al. 1998).
3. Their ground truth outcome metric is greater or equal to the censoring time of X. The patient
will potentially experience an adverse event after the censoring time tc.
Based on the Euclidean distance across the patient specific factors depicted in Table 1 (factors
with continuous values were normalized to have zero mean and standard deviation of one), we
find the k-nearest neighbors of X within the cohort outlined. We assign to the censored patient
X the average time to adverse event of their k-nearest neighbors. We used cross-validation to set
the parameter k = 50. The outcome of interest was the area-under-the-curve (AUC) performance
of the binary classification model presented in Section 4 (Figure 2). We selected the value of the
unsupervised learning model parameter according to the performance of the binary classification
model on the 10-year risk task. Our method allows us to build for every censored patient a unique
cluster of k-NN, introducing a personalization aspect in the estimation of TAE. See Figure 3 for
an illustration of our approach.
Our k-NN algorithm’s performance is R2 = 0.81 according to the following process:
1. Select a sample of the population which was not censored (the TAE is known).
2. Artificially generate a censoring time, sampled uniformly across the interval [1,3650] corre-
sponding to a day in the 10 year time frame.
3. Apply the k-NN algorithm to estimate the TAE and compare the results with the ground
truth that is known.
We impute the outcomes of 13,679 censored observations, following this approach. We create a
complete dataset that is further used for the creation and validation of the predictive and prescrip-
tive models.
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Figure 2 Graph of a Cross-validation results for the selection of the k parameter for the k-NN model.
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Figure 3 Illustration of the estimated survival curves for three censored patients based on the k-NN approach.
The vertical lines correspond to the time of censoring for each patient. Patients X and Y are 70 year old
Caucasian men. Patient X is overweight, does not smoke, and was prescribed calcium channel blockers as the only
form of medication. Patient Y is obese, diabetic, does not smoke, and was administered a CABG surgery along
with 7 different types of medications. The clinical exams of both Patients X and Y reported prehypertension and
normal levels of cholesterol. Patient Z is an 86 years old Caucasian man, who is an underweight smoker and was
prescribed ACE inhibitors, alpha blockers and diuretics. His clinical exams reported hypertension and near optimal
cholesterol levels. Notice that for all patients the survival function is decreasing. This indicates that the
probability of an adverse event is increasing since CHD is a chronic disease which aggravates in time.
4. The Binary Classifications Models
The first problem we addressed is the creation of personalized risk prediction models for CAD
patients. Our binary outcome of interest is the occurrence of an adverse event (stroke or heart
attack) within a 10-year time period. We fit a diverse set of state-of-the-art ML algorithms to the
data and compare their out-of-sample performance on the testing set. Table 4 provides a summary
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of the results for Logistic Regression, Random Forest (Breiman 2001), Boosted Trees (Chen and
Guestrin 2016), CART (Breiman et al. 1984), and Optimal Classification Trees (OCT) (Bertsimas
and Dunn 2017, 2019).
We split the n = 21,460 patients in 75% for Training and Validation and 25% for Testing, using
p = 31 patient characteristics (Table 1). Our sample includes all censored observations whose values
were imputed using the methodology described in Section 3. These observations were not excluded
as a higher sample size improved the model’s out-of-sample performance. A higher sample size had
a significant positive effect on the downstream performance of the binary classification models. We
evaluated the predictive power of the algorithm under additional random splittings of the data.
Thus, we ensured that the evaluation of the global algorithm was not sensitive to a particular split
of the dataset.
L2 regularization was used for the logistic regression model and cross-validation was employed
to set the hyper-parameters of each method. In the case of OCT and CART, we tuned the com-
plexity parameter, the maximum depth, and minimum bucket. Based on cross-validation results,
the number of greedy trees used for the Random Forest model was set to 500.
Our objective was to create an accurate model that would have high chances of affecting the
medical practice. Even though there has been a steep increase in publications that utilize artificial
intelligence and ML in the field of medicine, only a small proportion of those models have been
integrated into the healthcare system (Emanuel and Wachter 2019). Clinicians need actionable
insights and guidelines they can explain and understand (Nevin et al. 2018). Algorithms have
to satisfy this condition. Otherwise, the final outputs of these methods do not actually impact
the patients. The FDA (2017) validated such concerns by mandating the use of interpretable ML
models when it comes to medical decision making.
For this reason, we decided to focus on the model of the Optimal Classification Trees (OCT) algo-
rithm, which was proposed by Bertsimas and Dunn (2017), see also (Bertsimas and Dunn 2019).
This new supervised learning method uses modern mixed-integer optimization techniques to form
the entire decision tree in a single step, allowing each split to be determined with full knowledge of
all other splits. The OCT algorithm creates the entire decision tree in a holistic manner yielding
comparable but more interpretable results to well-established ML approaches, such as Random
Forest or Boosted Trees (Table 4). Notice that Random Forest (84.29%) yields better AUC results
compared to OCT (81.54%), although quite similar in terms of accuracy (81.88%, 81.45% respec-
tively). However, Random Forest grows multiple decision trees and assigns for each observation
the class that is indicated by the majority of the decision trees. OCT provides us with a single tree
whose branches can be easily explained to physicians. Each path leads to comprehensible clinical
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Out-of-sample
AUC
In-sample
AUC
Out-of-sample
Accuracy
In-sample
Accuracy
OCT 81.54% 81.35% 81.45% 81.36%
CART 73.33% 72.66% 80.23% 80.12%
Random Forest 84.29% 83.29% 81.88% 82.35%
Logistic regression 80.83% 82.21% 80.55% 80.98%
Boosted Trees 81.43% 82.76% 81.03% 81.27%
Baseline 73.51% 73.51%
Table 4 Results of the different ML algorithms used to predict the occurrence of an adverse event within 10
years after diagnosis. We consider as Baseline the simple model that predicts that no patient will experience an
adverse event. The term “Out-of-sample” signifies the performance of the model on the Test set and
“In-sample” on the Training set. The baseline refers to the naive approach of predicting for each observation the
most common class, namely no adverse event within 10 years from diagnosis.
decision rules that could positively affect the cardiovascular practice. Its model achieves superior
performance in both accuracy and AUC when compared to all other ML methods, including the
advanced ensemble algorithm of Boosted Trees. Moreover, Logistic Regression (80.83% AUC) is
more accurate compared to CART (73.33% AUC), but slightly under-performing with respect to
more sophisticated algorithms (81.43% AUC).
The final OCT model is depicted in Figures 4, 5, 6. Table 5 presents its ten most significant
variables. An analysis of the most predictive features follows below:
• Time in the System (TimeinSystem): the time that the patient has been observed in the
BMC database (from the first record until time of diagnosis t0). It serves as an indicator of
their medical condition and history information depth. TimeinSystem does not incorporate
any patient details after the time t0, avoiding the inclusion of survivorship bias in the data.
As shown in Figures 4, 5, 6, higher values of the TimeinSystem variable are associated with
leaves that predict positive outcomes for the patient. This result indicates that physicians
are more effective when they have extensive amount of information available and follow their
patients’ trajectories over longer periods of time.
• Prescription of Medication (Nitrates/ Beta Blockers/ Statins/ ACE Inhibitors): whether
a patient has been systematically treated with one particular type of medication. Depending
on the decision path of the tree, the risk of an adverse event might increase or decrease if
the medication has been prescribed. There need not be a causality relation for the changes
in risk. Only association can be deduced from such a model. However, these results reinforce
the argument that personalization in the treatment can indeed affect the survival of the CAD
population.
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• CABG/PCI: whether the patient has performed a revascularization procedure. We notice
that positive values in these two variables are associated with leaves that suggest pessimistic
patient prognoses. Diagnosed CAD patients with more severe symptoms of atherosclerosis are
usually suggested to perform at least one of these interventions (CABG, PCI) (Fihn et al.
2014).
• Patient Age at Diagnosis: the age of the patient at the time of diagnosis in the EMR
system. Across the model we notice that older populations are associated with higher risk,
confirming a wide range of CAD risk calculators published in the medical literature (Conroy
et al. 2003, Polonsky et al. 2010, Dagostino et al. 2008).
• HDL (mg/dL) levels: the HDL (mg/dL) levels from a blood test conducted at the time
of diagnosis. Depending on the position of the split in the tree, higher levels of HDL may
positively or negatively impact the ten year risk of CAD.
• Median Systolic Blood Pressure: the median of the systolic blood pressure measurements
recorded in the EMR across all visits in a window of three months before t0. We consider
the median due to the noise frequently encountered in systolic blood pressure measurements
(Tucker et al. 2017, Epstein 2014, Duan et al. 2019).
Feature Importance
Time in the System 27.40%
Prescription of Nitrates 19.80%
Prescription of Beta Blockers 15.01%
PCI operation 12.96%
Prescription of Statins 10.53%
CABG operation 3.23%
Patient Age at Diagnosis 2.87%
Prescription of ACE inhibitors 1.86%
HDL (mg/dL) levels 1.31%
Median Systolic Blood Pressure 1.06%
Table 5 Demonstration of the independent variable ranking in the OCT binary classification model. The
importance of each variable is measured as the total decrease in the loss function as a direct result of each split
in a tree that uses this variable. The results are normalized so that they sum to one.
4.1. Analysis of characteristic decision paths
We analyze distinctive risk profiles from the OCT model that provide interesting insights for the
management of CAD patients.
• Paths 1 & 2: Contain samples whose presence in the EMR was recorded only for two months
before the diagnosis. Leaf 1 refers to patients that are administered a PCI operation and leaf
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2 to those who perform a CABG surgery. Both paths associate extremely high risk to the
corresponding population.
• Paths 3 & 4: Refer to individuals who are present in the BMC system at least seven years.
They are not treated with PCI, neither with beta blockers nor statins. Their baseline risk of
an adverse event is 7.78%. However, this risk differs depending on the age group they belong.
Specifically, those individuals under 68 years old have 98.55% probability of avoiding a stroke
or heart attack over the next ten years. On the contrary, older patients have 18.11% chance
of experiencing an adverse event.
• Paths 5 & 6: Include patients who are present in the BMC system for at least two months and
are prescribed PCI but no CABG surgery. They are not treated with beta blockers nor statins
and their blood glucose levels are lower than 149 mg/dL. Their baseline risk of an adverse
event is 12.53%. This risk differs again depending on the age group they belong. Specifically,
those under 57 years old have 95.19% probability of avoiding a stroke or heart attack over the
next ten years. On the contrary, patients older than 57 years of age have 14.03% chance of
experiencing such an event.
Figure 4 Visualization of the first part of the OCT model. Paths 1 and 2 are indicated with blue arrows.
5. The Regression Models
Predicting the risk of an adverse event within a 10-year time frame is an important question that
we address in Section 4. However, a personalized prescriptive algorithm requires the creation of
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Figure 5 Visualization of the second part of the OCT model. Paths 3 and 4 are indicated with blue arrows.
accurate regression models that, given the condition of a patient, estimate the exact TAE for each
potential treatment. We leveraged various state-of-the-art ML methods, both interpretable and
non-interpretable, to generate a set of estimations at an individual level (Breiman et al. 1984,
Breiman 2001, Bertsimas and Dunn 2017, 2019, Chen and Guestrin 2016). We trained a separate
model for each combination of method and treatment using as sample population patients that
exclusively received this regimen. For example, we applied the Random Forest algorithm to generate
five predictive models that correspond to CABG, PCI, Drugs 1, 2, and 3. We followed the same
process for CART, Linear Regression, Boosted Trees, and Optimal Regression Trees (ORT). As
in the classification task, we applied cross-validation to determine the hyper-parameters of each
model, including the complexity parameter, the maximum depth, and minimum bucket for ORT
and CART. Based on the cross-validation results for the regression task, the number of greedy trees
for the Random Forest model was set to 250 in contrast to 500 that were chosen for the binary
classification outcome. We used L2 regularization for the linear regression model. Table 6 provides
a summary of each method’s out-of-sample performance for every treatment option in terms of the
R2 metric.
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Figure 6 Visualization of the third part of the OCT model. Paths 3 and 4 are indicated with blue arrows. This
component of the tree refers only to patients who were administered PCI and are observed in the System for at
least 60 days.
ORT CART
Random
Forest
Linear
Regression
Boosted
Trees
CABG 73.14% 71.91% 83.00% 80.32% 80.06%
PCI 68.30% 67.73% 74.58% 73.21% 73.21%
Drugs 1 78.64% 75.35% 83.92% 82.94% 82.48%
Drugs 2 73.46% 72.56% 80.02% 79.98% 79.50%
Drugs 3 67.10% 69.03% 77.71% 75.34% 75.29%
Table 6 Results of supervised ML algorithms to predict the TAE since diagnosis. We report the
“Out-of-sample” R2 performance of each model on the Test set.
The results from Table 6 indicate that Random Forest outperforms the other methods in all
tasks in terms of the R2 metric. CART, on the other hand, appears as the least performing method
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across all tasks. ORT have an edge over the greedy tree-based approach, other than in the case
of category “Drugs 3”. We observe that Linear Regression and Boosted Trees have comparable
performance for all types of treatment. We will leverage all these models as the main component
of our prescriptive algorithm, presented in Section 6.
We created separate models for each treatment population to avoid biases in the prediction due
to the existing treatment prescription patterns in the EMR (Gianfrancesco et al. 2018). Our goal
was to identify, for each patient, what is the therapy that would maximize their TAE. Therefore,
a distinction was needed between the different populations that received each treatment option.
The existing regimen allocation process could have significantly biased the prescriptive algorithm
if included as an independent feature in the set of covariates X (Schulz et al. 1995). For instance,
if physicians in BMC prescribed CABG only to the younger population, the ML model would not
have been able to distinguish between the effect of CABG and the age of the patient.
6. ML4CAD: The Prescription Algorithm
The regression models serve as the basis for the prescription algorithm, utilizing the point predic-
tions as counterfactual estimations. The objective of the prescription algorithm is to understand
the potential effect of every therapy that each patient would have experienced, had it been pre-
scribed to them. For example, knowing the outcome of patient X who received CABG surgery, we
aim to estimate the outcome metric of a PCI intervention and for each of the Drugs options. We
present ML4CAD, a personalized prescriptive algorithm that utilizes multiple ML models at once to
identify the most effective therapy for CAD patients. Our method is structured as follows:
1. We impute the missing values of the patient characteristics (Table 1) using a state-of-the-art
optimization framework (Bertsimas et al. 2018).
2. We compute the TAE for right censored patients.
3. We split the population into training and test sets. The training set is used to train the regres-
sion models and the test set is utilized to assess the predictive and prescriptive performance
of the algorithm.
4. We train a separate regression model for each treatment option for all predictive algorithms
to estimate the TAE. The set of covariates X ′ used to create the predictive models does not
include any features that refer to the treatment options (see Table 1 for a summary of the
independent features and Table 2 for the list of prescription options).
5. We use all models to get estimations of the TAE for each treatment option and every patient
in the test set. Thus, we have at our disposal a table of estimations for any new individual
considered. Table 7 provides an illustration of the output for patient X.
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6. We select the most effective treatment for the patient according to a voting scheme among
the ML methods:
(a) If the majority of the regression models votes a single treatment (regimen with the best
expected effect), the algorithm recommends this therapy to the physician. In the example
of patient X (see Table 7), ML4CAD suggests the prescription of CABG.
(b) If there are ties between the different therapies (i.e., two methods suggest Drugs 1 and
two others indicate Drugs 2), then the votes get weighted by the out-of-sample accuracy
of the predictive models. For the analysis of this paper, the R2 metric was used.
7. The final TAE is computed as the average of the ML methods whose suggestion agreed with
the algorithm recommendation.
ML Method CABG PCI Med. 1 Med. 2 Med. 3
ORT 4.65 4.59 3.89 3.76 3.54
CART 7.13 3.38 6.10 4.16 3.96
Random Forest 5.77 4.93 5.44 4.26 4.49
Linear Regression 5.75 3.53 5.75 4.17 4.44
Boosted Trees 4.08 6.28 5.39 5.31 3.37
Table 7 Estimations of TAE (years) for patient X from the five ML methods considered for each treatment
option. We highlight the best treatment option for each ML model. Note that four out of the five models agree
on the CABG recommendation.
ML4CAD provides a new framework for personalized prescriptions which is structured on the
plurality of different ML models. In contrast to the simple Regress and Compare approach, it
combines multiple ML models to identify the most beneficial treatment option. The validity of the
algorithm’s recommendations gets reinforced by an increasing number of underlying ML models
that provide accurate estimations of the counterfactuals. In other words, the user gains more
confidence in the capability of the algorithm to identify the optimal therapy the more models
are available for comparison. This methodology also allows for transparency towards the decision
maker. Potential recommendations can be compared at an individual level to be decided what
would be the best option for each particular case.
Bridging the gap with practitioners
We created an online ML4CAD application for physicians who would be interested to inform their
decision making process using our personalized algorithm. Practitioners can now have access to
our website (https://personalized.shinyapps.io/ML4CAD/), where they are able to quickly test
the recommendations of the algorithm on new patient data. Figure 7 shows an image of the main
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Figure 7 Treatment Allocation patterns between different ML methods.
application dashboard. The platform computes online a table similar to Table 7, demonstrating
to the user all the available options and their projected outcomes. The final ML4CAD suggestion
is highlighted on the right of the screen. A detailed comparison of the out-of-sample performance
of all ML models across the five treatment tasks is also available. Moreover, clinicians can view
aggregate results about the treatment allocation mechanism according to different demographic
features such as gender, ethnicity, or age group. With this application we aspire to open the “black-
box” of ML recommendation to the medical community. The latter can now leverage this tool as
an assistance to its decision making process and prolong the life expectancy of its patients.
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Prescriptive algorithm evaluation
Assessing the quality of the prescriptive algorithm poses a challenge. We do not have at our disposal
data that indicate the TAE for all counterfactual outcomes of each patient. We created appropriate
metrics that provide an objective evaluation framework of the algorithm’s performance. We define
the problem as follows, let:
• p be a variable that takes values in the set [T ] of all the prescriptive options;
• j be a variable that takes values in the set [M] of all the predictive models;
• zi be the treatment that patient i followed at the standard of care;
• ti be the TAE for patient i and treatment zi;
• τi be the treatment recommendation of ML4CAD for patient i;
• θji be the treatment recommendation of machine learning model j ∈ [M] for patient i using a
simple “Regress and Compare approach”;
• gji (p) be the estimated TAE for patient i for treatment p from the regression model j, where
j ∈ [M];
• yi(p) to be the estimated TAE for patient i when ML4CAD recommends treatment p;
• tp average TAE observed in the data for all patients who were prescribed treatment p.
Using the notation above, the expected TAE for patient i is according to ML4CAD:
yi(τi) = 1
K
∑
j∶argmaxp gji (p)=τi
gji (τi), K = ∣j ∶ argmax
p
gji (p) = τi∣, i ∈ [n]. (2)
We evaluate the quality of the algorithm’s personalized recommendations based on the following
metrics:
1. Prescription Effectiveness and Robustness:
The goal of the first metrics is to compare the performance of the ML4CAD recommendations
with the regimens prescribed at the standard of care. Due to the uncertainty in counterfactual
estimation, we consider different predictions of the TAE and a multitude of ground truths. Our
baseline ground truth refers to realizations of TAE that we observe in the BMC database. This
ground truth provides us with the exact TAE associated to the treatment regimen that was
prescribed by the physicians at the hospital. Alternative ground truths refer to estimations of
the TAE by treatment-based regression models.
• Prescription Effectiveness (PE)
We fix, for each patient i ∈ [n], the treatment suggestion τi from the ML4CAD algorithm.
We know the outcome ti for treatment choice zi (observed in the data - baseline ground
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truth). Thus, comparing the prescription effectiveness of the ML4CAD versus the standard
of care would be equal to:
PE(ML4CAD) = 1
n
n∑
i=1 yi(τi)− ti, i ∈ [n]. (3)
ML4CAD averages the TAE projected by the regression models that agree on the most
beneficial treatment for patient i, namely τi. We can evaluate the prescription effectiveness
of this recommendation by considering each ML model in isolation. Each regression model
j provides for patient i and regimen p an estimation gji (p). Therefore, if we fix p = τi, we
can get an evaluation of the projected TAE and compare it to the standard of care.
PE(MLj) = 1
n
n∑
i=1 g
j
i (τi)− ti, ∀j ∈ {1, . . . ,M}, i ∈ [n]. (4)
Comparing multiple ML estimations for the TAE of the recommendation τi renders the
results more credible to biases of a specific predictive algorithm.
• Prescription Robustness (PR)
The PE metric measures the effect of the ML4CAD recommended therapies against a fixed
given ground truth from the EMR of the BMC. Nevertheless, knowing that each patient
i was given a treatment ti, we can generate alternative ground truths. We can, then,
evaluate the benefit of the personalization approach against those. Each ground truth
corresponds to an estimation of what would happen to patient i if ML model j was an
oracle that knew the reality and the effects of treatment zi.
PR(MLj,k) = 1
n
n∑
i=1(gji (τi)− gki (zi)), ∀j,k ∈ [M], i ∈ [n]. (5)
In this setting, decisions τi, zi are fixed and we evaluate all the combinations between
Random Forest, CART, ORT, Boosted Trees, and Linear Regression. We include also the
case where ML4CAD is used to estimate the effect of τi but not the one of ti.
PR(ML4CADk) = 1
n
n∑
i=1(yi(τi)− gki (zi)), ∀k ∈ [M], i ∈ [n]. (6)
The goal of this metric is to evaluate the robustness of the treatment effect under
different ground truths. In Section 7, we perform an extensive comparison over all methods
and ground truths considered (see Table 8). We introduce this approach to avoid biased
estimates of performance. The latter could not have been avoided if we were comparing
our results only to the baseline ground truth.
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2. Prediction accuracy of TAE:
R˜2(ML4CAD) = 1− ∑i∈S(yi(zi)− ti)2∑i∈S(tzi − ti)2 , S = {i ∶ τi = zi}, i ∈ [n]. (7)
This metric follows the same structure as the well-known coefficient of determination R2.
We apply it for each patient i ∈ S, the set of all samples where there is agreement between
the ML4CAD and baseline prescription; S = {i ∶ τi = zi}. Similar to the original measure, the
known outcome ti is compared to the estimated treatment effect yi(zi) and to a baseline
estimation. The latter in our case is tzi , the mean TAE observed in the data for all patients who
were prescribed treatment zi. The adjusted coefficient of determination R˜
2 helps us evaluate
whether the outcome that ML4CAD predicts for the known counterfactuals is accurate or not.
It is impossible to evaluate the prescriptive algorithm across all treatment options. Only one
out of the five is actually realized in practice. We focused on comparing for each patient the
TAE according to the algorithm versus the one present in the data only for the cases where
there was agreement between the two. This estimation, even though limited, provides us with
a good baseline regarding the accuracy of our recommendations. We can extend the use of
this metric to the “Regress and Compare” approach. Thus, we can estimate the R˜2(MLj) of
each predictive model j ∈ [M].
R˜2(MLj) = 1− ∑i∈S(gji (zi)− ti)2∑i∈S(tzi − ti)2 , S = {i ∶ θji = zi}, i ∈ [n]. (8)
3. Degree of ML agreement (DMLA):
This measure refers to the degree of agreement among the ML models (DMLA) with the
recommended treatment τi. For each patient, we count the number of methods that agree
on the ML4CAD suggested treatment τi. We report the distribution of this metric across the
whole population. Cases where there is high degree of agreement are associated with higher
confidence on the suggested prescription. On the contrary, we are less confident in cases where
there is misalignment between the ML models regarding the best treatment option.
7. Prescriptive algorithm results
In this Section, we present numerical results with respect to the evaluation metrics introduced in
Section 6. We provide insights regarding different sample population subgroups. We also discuss
new treatment allocation patterns based on ML4CAD recommendations.
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7.1. Prescription Effectiveness (PE) and Robustness (PR)
We summarize our results with respect to the PE and PR metrics in Table 8. The first table column
corresponds to PE (baseline ground truth), whereas the rest of the columns refer to PR (ML-based
ground truths). Table 8 presents the expected relative gain in TAE of ML4CAD over the baseline. Its
values demonstrate the average benefit in years of TAE when comparing the current and ML4CAD
treatment allocation plan across different estimation models. Each ground truth (column) refers
to alternative estimations of the TAE under the current treatment allocation plan. Thus, if the
ground truth is the baseline (BMC Database), the suggested times correspond the TAE observed
in the data. When the ground truth is set to be the ORT algorithm, the predicted times gORTi (zi)
mirror ORT estimations when the treatment allocation is fixed to the physicians’ decisions from the
hospital (zi). Each prediction model (row) provides us with a continuous prediction of a patient’s
TAE when the treatment allocation plan is set by the ML4CAD algorithm (τi). Thus, the values
in Table 8 correspond to the metrics defined in Equations 4 (first column) and 5 (subsequent
columns).
Ground Truth
Estimation Model Baseline ORT CART
Random
Forest
Linear
Regression
Boosted
Trees
ML4CAD 1.101∗ 1.162 1.158 1.140 1.178 1.283
ORT 0.779 0.840 0.835 0.818 0.855 0.961
CART 0.923 0.983 0.979 0.965 0.999 1.105
Random Forest 0.757 0.818 0.813 0.796 0.833† 0.939
Linear Regression 0.485 0.546 0.541 0.524 0.561 0.667
Boosted Trees 0.591 0.652 0.647 0.630 0.667 0.773
Table 8 Comparison of the “Prescription effectiveness” (PE) and “Prescription robustness” (PR) metrics for
all estimation models and ground truths considered. The first column (Baseline) presents results with respect to
the PE metric and refers to the TAE observed in the BMC database. All subsequent columns refer to the PR
measure. Each of them represents a distinct ground truth. All units are shown in years. See Equations 4,3,5.
When compared to the current allocation scheme, our prescription algorithm improves the aver-
age TAE by 24.11%, with respect to the PE metric, with an increase from 4.56 to 5.66 years
(1.102). Column “Baseline (PE)” of Table 8 summarizes the results with respect to all regression
models considered. ML4CAD provides the most optimistic estimations. It suggests a higher TAE
∗The PE of the algorithm when the estimation model gj is ML4CAD and the ground truth relates to the patient
outcomes observed in the BMC database (See Equation 4).
†The PR of the algorithm when CART is the chosen estimation model gj for the prescriptions zi, i ∈ [n] and the
ground truth outcomes are computed according to the Linear Regression model gk (See Equation 5).
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versus its counterparts by at least 0.18 years (2 months). Linear Regression appears to be the most
pessimistic method with an average benefit over the baseline of 6 months (0.59 years). ORT and
Random Forest provide similar estimations of 0.77 and 0.75 years of improvement, respectively.
The comparable performance of the various estimation models presented in Table 8 reinforces the
credibility of the prescription algorithm. We show that there is agreement between the potential
improvement in the average TAE by an alternative treatment allocation scheme. Even in cases
where we include ML models that did not participate in the ML4CAD recommendation, there is
substantial benefit in the patients’ life expectancy.
We observe better results across all age and ethnicity patient subgroups and for both genders.
The benefit of using the algorithm was 17.09% (0.9 years) for Black patients, 29.03% (1.16 years) for
Caucasian patients and 58.41% (1.86 months) for Hispanic patients. We also note 22.5% (0.99 years)
improvement for patients 65−80 years of age and 46.9% (1.58 years) for patients aged 80 or older.
Male patients are expected to increase their time from 4.62 years to 5.73 (24.19% improvement)
similar to female patients (from 4.42 years to 5.48). The performance of the prescriptive algorithm
for selected patient subgroups compared to the BMC baseline is summarized in Figure 8.
In terms of the PR metric, our results demonstrate a consistent improvement of the patient
population TAE across all ground truths and estimation models. Table 8 summarizes the results
of our analysis. We note that ML4CAD achieves the highest benefit when compared to all alternative
scenarios of outcome realization. This is due to the incorporation of the voting system for the
selection of the most effective treatment that accounts for all ML models. We show that even in
the case of more pessimistic estimators, such as Boosted Trees or Linear Regression, there is a
substantial benefit compared to the standard of care. Our approach does not guarantee optimality
for the treatment selection problem. Nevertheless, it is experimentally shown that it can bring
about substantial benefit to the CAD population.
We can also identify for each estimation model combinations with ground truths that outperform
the rest of the alternatives. All methods demonstrate the highest improvement when associated
with the Boosted Trees ground truth. For example, the ORT and CART model increase the average
TAE by 0.96 and 1.10 years respectively. The next most optimistic contestant is Linear Regression.
This is due to the fact that some methods on average overestimate or underestimate the expected
TAE, translating these discrepancies in the PR metric.
7.2. Prediction accuracy of TAE
The “prediction accuracy of TAE” for the proposed prescriptive algorithm is R˜2(ML4CAD) = 78.7%.
Table 9 provides a summary of the results for both the suggested method as well as “Regress and
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Figure 8 Comparison of the expected years to adverse event after diagnosis for the age and ethnicity subgroups
considered. The difference between the two bars for each sub-population refers to the prescription effectiveness
(PE) of the algorithm for each respective patient group. “Current.TAE” refers to the outcomes observed in the
EHR of the BMC. “ML4CAD.TAE” represents the expected TAE according to the prescription algorithm.
Compare” approaches from the baseline ML models. ML4CAD achieves better performance compared
to the single prediction model counterparts. Aggregated predictions from different regression models
lead to more accurate outcomes. The suggested voting scheme, not only reduces the uncertainty
and bias of the estimations (See Section 7.1), but also results in highly accurate predictions.
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Method ML4CAD ORT CART Random Forest Linear Regression Boosted Trees
R˜2 78.70% 72.68% 70.54% 77.25% 76.66% 76.59%
Table 9 Results summary for the Prediction Accaracy of TAE (R˜2) metric.
7.3. Degree of ML agreement (DMLA)
The majority of the ML4CAD recommendations zi are based on a common suggestion between at
least three distinct ML models. Specifically, in 14.53% of the patients all methods suggest the same
treatment for each individual. In 26.74% of the cases there is agreement between four models and in
34.48% of the observations three methods participate in the decision. Only in 0.26% of the samples,
each regression model suggests a different prescription. In such cases, the ML4CAD recommendation
is solely based on the suggestion of the most accurate one.
Table 10 provides detailed results for each treatment option. The last table column summarizes
the results as a function of the total population. Each treatment specific column presents the
proportional degree of agreement for all patients for which this treatment was suggested. Thus,
we notice that CABG as well as Drugs 1 & 2 recommendations are, on average, more confident
compared to Drugs 3 or PCI due to the higher degree of agreement. This is particularly true in
the case of Drugs 1, where 85.49% of the patients three out of the five methods voted for the same
regimen.
Number of ML methods
that agree with the
recommendation
CABG
Drugs
1
Drugs
2
Drugs
3
PCI
Population
Proportion
1 1.13% 0.22% 0.00% 0.00% 0.00% 0.26%
2 20.82% 14.29% 41.54% 59.65% 49.10% 23.99%
3 35.41% 32.30% 43.98% 36.23% 39.07% 34.48%
4 27.34% 33.58% 13.26% 3.64% 10.28% 26.74%
5 15.30% 19.61% 1.22% 0.47% 1.54% 14.53%
Table 10 Degree of ML Agreement between the models analyzed for each treatment option as well as a
function of the overall test population.
7.4. Treatment Allocation Patterns
In this section, we present insights regarding the ML4CAD treatment allocation patterns and we
perform comparisons with the standard of care at the BMC. Our method agrees with the physicians’
decisions in 28.24% of the cases. The results indicate a shift towards drug therapy and CABG,
reducing the overall proportion of PCI (from 18.84% to 6.04%). The prediction model indicates
that patients with severe symptoms do not benefit significantly from a PCI versus a CABG surgery
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due to the eminent need for revascularization. Figure 9 illustrates a significant shift towards “Drugs
1” for both women and men. The algorithm also recognizes that treatment “Drugs 2” is less
effective on female patients versus male. The ML4CAD allocation is in agreement with the most
recent guidelines published by the American Heart Association (Stout et al. 2018). In the vast
majority of cases, a combination of antihypertensive drugs (Blockers) with lipid lowering treatment
(statins) is suggested. The overall proportion of the population that is recommended an invasive
intervention is reduced due to the significant decline of PCI operations.
Figure 10 illustrates a comparison of the treatment allocation patterns between the ML4CAD
algorithm, individual “Regress and Compare” models, and the standard of care we observe in the
data. The graph demonstrates an agreement across all methods other than CART to increase the
proportion of the population under “Drugs 1”. The ML4CAD algorithm is more aligned with the
Random Forest policy due to the high predictive performance associated with the latter. We also
note the reduction of “Drugs 2 & 3” across all methods. In the case of CABG there is disagreement
between the ML models. Boosted Trees and Linear Regression suggest a significant raise in the
proportion of CABG surgery at the expense of “Drugs 1”. On the other hand, ORT, Random
Forest, and CART identify CABG as the optimal therapy for a lower proportion of the patient
population.
ML4CAD Allocation
Treatment CABG Drugs 1 Drugs 2 Drugs 3 PCI
Current
Allocation
CABG 1.3% 4.1% 0.9% 1.6% 0.8%
Drugs 1 2.3% 22.1% 3.7% 2.1% 1.7%
Drugs 2 2.0% 12.3% 2.0% 0.2% 1.0%
Drugs 3 3.2% 16.3% 1.0% 1.4% 1.1%
PCI 2.2% 9.5% 1.3% 4.5% 1.4%
Table 11 Allocation of patients in the treatment options based on the standard of care and ML4CAD.
8. Discussion and Conclusions
Combining historical data from a large EMR database and state-of-the-art ML algorithms resulted
in an average TAE benefit of 24.11%% (1.1 years) for patients diagnosed with CAD. Our results
show that differing medication regimens and revascularization strategies may produce varying clin-
ical outcomes for patients. The use of ML may facilitate the identification of the optimal treatment
strategy. Such efforts could directly address the primary objectives of the clinical cardiovascular
practice, leading to symptoms reduction and an increase in the population life expectancy. Our
findings uncover the greatest clinical benefit in medical therapy changes, consistent with themes
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Figure 9 Population allocation to treatments split by gender.
Figure 10 Treatment Allocation patterns between different ML methods.
that have emerged in clinical trials (Boden et al. 2007). The optimal revascularization strategy in
patients with multi-vessel CAD is an area of active investigation, with efforts focused on identifying
which patient subgroups may benefit from different revascularization procedures (Farkouh et al.
2012). Our technique may add clarity to this clinical challenge.
Our prescriptive approach is accurate, highly interpretable, and flexible for other healthcare
applications. The use of multiple ground truths derived from independent ML models renders
credibility to the results. In prescriptive problems where counterfactual outcomes cannot be evalu-
ated against a known reference, leveraging multiple ML models can reduce the uncertainty behind
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suggested recommendations. For this reason, we believe that metrics such as the prescription effec-
tiveness and robustness are key to the validation process.
Moreover, our online application bridges the gap between clinicians and the algorithm. Users
can directly and simultaneously interact with multiple ML models from a user-friendly interface.
Our method should easily accommodate alternative cardiovascular disease-management approaches
within specific disease subpopulations, such as arrhythmia and valvular disease management. A
novelty of our approach is in the personalization of the decision-making process. It incorporates
patient-specific factors, and provides guidelines for the physician at the time of diagnosis / clinical
encounter. We believe this personalization is the primary driver of benefit relative to the standard
of care. Similarly, there is emerging data on use of ML techniques to improve cardiac imaging
phenotyping of cardiac disease states, such as heart failure (Omar et al. 2017).
The widespread use of EMR in clinical medicine was initially viewed with much optimism,
however more recently it has been met with frustration by clinical providers. Concerns are being
raised over the administrative burden to document the EMR and the resultant development of
clinician “burn out”. The methodology presented in this paper identifies a mechanism to harness
the power of the EMR in an effort to improve patient care and make it more personalized. It is
true that the clinical acumen developed over time spent caring for patients cannot be replaced by
algorithms. Nevertheless, the prospect of ML to guide clinicians and complement clinical decision
making may help improve clinical outcomes for patients with cardiovascular and other diseases
(Ebinger et al. 2016).
Our work has several limitations due to the nature of the EMR. Patients were not randomized
into treatment groups. Our data do not include socioeconomic factors or patient preferences that
may be important in treatment decisions, such as income or fear of invasive treatment strategies.
Although our matching methodology controls for several confounding factors that could explain
differences in treatment effects, we can only estimate counterfactual outcomes. In addition, the
study population of BMC is not representative of the general U.S. population. Moreover, we should
consider that the accuracy of the prediction model is limited, though significantly better than the
baseline model. It leaves room for improvement in that field by including new variables and further
risk factors that are associated with CAD. Due to lack of sufficient data, we did not take into
account different types of CABG surgery (i.e. arterial versus venous conduits) and PCI (i.e. newer
versus older generation drug eluting stents, or bare metal stents versus drug eluting stents). Should
more data were available, we could further differentiate the prescription categories beyond the five
we include in this analysis, including drug specific recommendations. Moreover, the algorithm does
not agree with the standard of care in most cases. This result indicates that new personalization
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techniques would need further input from clinicians that was not originally recorded in the EMR.
Future research could address the issue of right censored patients with different approaches, which
incorporate the time varying effects of the explanatory variables using optimization rather than
heuristic methodologies. The ultimate validation of our algorithm would be the realization of a
clinical trial. There we would be able to test the personalized recommendation to patients directly
utilizing their EMR from the hospital system.
Despite these limitations, our approach establishes strong evidence for the benefit of individualiz-
ing CAD care. To our knowledge, this work represents the first ML study in treating cardiovascular
disease and serves as a proof of concept. Moreover, the success of this data-driven approach invites
further testing using datasets from other hospitals and patient populations. That includes care
settings that contain more detailed information regarding the patients’ condition, such as electro-
cardiogram findings and exercise and other lifestyle factors. The algorithm could be integrated in
practice into existing EMR systems to generate dynamically personalized treatment recommenda-
tions. Testing the prescriptive algorithm in a clinical trial setting could provide conclusive evidence
of clinical effectiveness. As large-scale genomic data become more widely available, the algorithm
could readily incorporate such data to reach the full potential of personalized medicine in cardio-
vascular disease care. Our work is a key step toward a fully patient-centered approach to coronary
artery disease management and the application of modern analytics in the medical field.
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Appendix
Overall
Population
Training
Set
Validation
Set
Testing
Set
Gender - Male 28.63% 28.38% 28.82% 29.15%
Diabetic 46.15% 46.03% 46.12% 46.45%
Smoking 21.47% 21.31% 21.68% 21.73%
Hypertension - Family History 13.43% 13.72% 13.04% 12.96%
Diabetic - Family History 13.43% 13.42% 13.46% 13.43%
Table 12 Distribution of the key categoric variables considered in the model split by Training, Validation and
Testing set.
Sample Total Population Training Set Validation Set Testing Set
Metrics Mean
Stand.
Dev.
Mean
Stand.
Dev.
Mean
Stand.
Dev.
Mean
Stand.
Dev.
Age 63.08 13.21 63.00 13.34 63.02 13.25 63.21 13.03
BMI 29.83 10.46 29.00 10.11 30.00 10.54 29.83 10.23
HDL 43.03 10.94 43.00 10.96 43.03 10.94 43.08 10.92
LDL 113.44 28.75 113.41 28.84 113.47 28.98 113.49 28.62
Diastolic
Blood Pressure
78.21 11.22 78.29 11.47 78.28 11.22 78.10 10.84
Systolic
Blood Pressure
137.85 20.99 137.94 21.06 137.93 20.87 137.72 20.90
Time in
the System
1632.31 1347.58 1636.85 1354.58 1636.90 1338.90 1625.51 1337.05
Table 13 Mean and standard deviation of continuous variables considered in the model split by Training,
Validation and Testing set.
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